MIRASOL, F. (2021). Biopharma Industry is Seeing Merit in Early Preclinical Strategies: The biopharma industry is seeing more merit in strategizing clinical and commercial drug development as early as the preclinical phase. BioPharm International, 34(11), 36-38.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
MIRASOL, FELIZA. "Biopharma Industry Is Seeing Merit in Early Preclinical Strategies: The Biopharma Industry Is Seeing More Merit in Strategizing Clinical and Commercial Drug Development as Early as the Preclinical Phase."
BioPharm International 34, no. 11 (2021): 36-38.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
MIRASOL, FELIZA. "Biopharma Industry Is Seeing Merit in Early Preclinical Strategies: The Biopharma Industry Is Seeing More Merit in Strategizing Clinical and Commercial Drug Development as Early as the Preclinical Phase."
BioPharm International, vol. 34, no. 11, 2021, pp. 36-38.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.